{
  "$schema": "folio-library-document/v1",
  "id": "10665-97885",
  "title": "The immunological basis for immunization series: module 16: mumps",
  "variant": "pdf",
  "pages": 44,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Cover",
      "number": null,
      "page": 1,
      "pageLabel": "i",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": null
    },
    {
      "level": 1,
      "title": "Contents",
      "number": null,
      "page": 5,
      "pageLabel": "iii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-contents"
    },
    {
      "level": 1,
      "title": "Abbreviations and acronyms",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-abbreviations-and-acronyms"
    },
    {
      "level": 1,
      "title": "Preface",
      "number": null,
      "page": 9,
      "pageLabel": "vii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-preface"
    },
    {
      "level": 1,
      "title": "Mumps disease and virus",
      "number": "1",
      "page": 11,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-1-mumps-disease-and-virus"
    },
    {
      "level": 2,
      "title": "Mumps disease",
      "number": "1.1",
      "page": 11,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-11-mumps-disease"
    },
    {
      "level": 2,
      "title": "Mumps virus",
      "number": "1.2",
      "page": 12,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-12-mumps-virus"
    },
    {
      "level": 2,
      "title": "Mumps vaccines",
      "number": "1.3",
      "page": 12,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-13-mumps-vaccines"
    },
    {
      "level": 1,
      "title": "Immunological response to natural infection",
      "number": "2",
      "page": 17,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-2-immunological-response-to-natural-infection"
    },
    {
      "level": 2,
      "title": "Antibody response to mumps infection in unvaccinated individuals",
      "number": "2.1",
      "page": 17,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-21-antibody-response-to-mumps-infection-in-unvac"
    },
    {
      "level": 2,
      "title": "Cell-mediated immunity following natural mumps disease",
      "number": "2.2",
      "page": 17,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-22-cell-mediated-immunity-following-natural-mump"
    },
    {
      "level": 2,
      "title": "Maternal antibody",
      "number": "2.3",
      "page": 18,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-23-maternal-antibody"
    },
    {
      "level": 2,
      "title": "Duration of immunity to natural mumps infection",
      "number": "2.4",
      "page": 18,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-24-duration-of-immunity-to-natural-mumps-infecti"
    },
    {
      "level": 1,
      "title": "Immunological response to vaccination",
      "number": "3",
      "page": 19,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-3-immunological-response-to-vaccination"
    },
    {
      "level": 2,
      "title": "Antibody response following vaccination",
      "number": "3.1",
      "page": 19,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-31-antibody-response-following-vaccination"
    },
    {
      "level": 2,
      "title": "Cell-mediated immunity following mumps vaccination",
      "number": "3.3",
      "page": 21,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-33-cell-mediated-immunity-following-mumps-vaccin"
    },
    {
      "level": 2,
      "title": "Duration of immunity to mumps vaccination",
      "number": "3.4",
      "page": 21,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-34-duration-of-immunity-to-mumps-vaccination"
    },
    {
      "level": 2,
      "title": "Correlates of immunity",
      "number": "3.5",
      "page": 22,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-35-correlates-of-immunity"
    },
    {
      "level": 1,
      "title": "Laboratory diagnosis of mumps",
      "number": "4",
      "page": 24,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-4-laboratory-diagnosis-of-mumps"
    },
    {
      "level": 2,
      "title": "Virological methods",
      "number": "4.1",
      "page": 24,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-41-virological-methods"
    },
    {
      "level": 2,
      "title": "Serological methods",
      "number": "4.2",
      "page": 24,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-42-serological-methods"
    },
    {
      "level": 2,
      "title": "Diagnostic challenges",
      "number": "4.3",
      "page": 25,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-43-diagnostic-challenges"
    },
    {
      "level": 1,
      "title": "Vaccine performance",
      "number": "5",
      "page": 26,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-5-vaccine-performance"
    },
    {
      "level": 2,
      "title": "Vaccine efficacy",
      "number": "5.1",
      "page": 26,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-51-vaccine-efficacy"
    },
    {
      "level": 2,
      "title": "Vaccine effectiveness",
      "number": "5.2",
      "page": 26,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-52-vaccine-effectiveness"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 30,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-references"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 5,
      "labelStart": "i",
      "labelEnd": "iii",
      "words": 750,
      "summary": {
        "text": "The front matter of Module 16 on mumps in WHO's Immunological Basis for Immunization series, by Huong McLean, Carole Hickman and Jane Seward. It contains the title pages, cataloguing data and keywords, copyright notice and standard WHO disclaimers. It states that responsibility for the views in the module rests with its authors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "huong mclean",
          "heading": false
        },
        {
          "term": "jane seward",
          "heading": false
        },
        {
          "term": "carole hickman",
          "heading": false
        },
        {
          "term": "immunization series",
          "heading": false
        },
        {
          "term": "organization concerning",
          "heading": false
        },
        {
          "term": "immunological basis",
          "heading": false
        },
        {
          "term": "mumps",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        }
      ],
      "extract": "Immunization, Vaccines and Biologicals The Immunological Basis for Immunization Series Module 16: Mumps Immunization, Vaccines and Biologicals The Immunological Basis for Immunization Series Module 16: Mumps WHO Library Cataloguing-in-Publication Data The immunological basis for immunization series: module 16: mumps / by Huong Q Mclean, Carole J Hickman and Jane F Seward. (Immunological basis for immunization series",
      "extractCut": true,
      "blocks": [
        "library/10665-97885/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-contents",
      "number": null,
      "title": "Contents",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 7,
      "labelStart": "iii",
      "labelEnd": "v",
      "words": 110,
      "summary": {
        "text": "The table of contents of the mumps module, listing sections on the disease and virus, vaccines, immune response to infection and vaccination, laboratory diagnosis, vaccine performance and references.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "natural mumps",
          "heading": false
        },
        {
          "term": "mumps vaccination",
          "heading": false
        },
        {
          "term": "mumps infection",
          "heading": false
        },
        {
          "term": "mumps disease",
          "heading": false
        }
      ],
      "extract": "Abbreviations and acronyms..............................................................................................v Preface............................................................................................................................... vii 1. Mumps disease and virus.......................................................................................1 1.1 Mumps disease",
      "extractCut": true
    },
    {
      "id": "sec-001-abbreviations-and-acronyms",
      "number": null,
      "title": "Abbreviations and acronyms",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 9,
      "labelStart": "v",
      "labelEnd": "vii",
      "words": 75,
      "summary": {
        "text": "Lists the abbreviations and acronyms used in the mumps module, mostly immunology, laboratory and viral protein terms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "protein",
          "heading": false
        },
        {
          "term": "acronyms",
          "heading": true
        },
        {
          "term": "nucleoprotein",
          "heading": false
        },
        {
          "term": "phosphoprotein",
          "heading": false
        }
      ],
      "extract": "acronyms CI confidence interval CMI cell-mediated immunity CTL cytotoxic T-cell DNA deoxyribonucleic acid EIA enzyme immunoassay ELISA enzyme-linked immunosorbent assay F fusion protein HLA histocompatibility leukocyte antigen HN haemagglutinin-neuraminidase protein Ig immunoglobulin L large protein M matrix protein MMR measles, mumps, and rubella NP nucleoprotein P phosphoprotein PAHO Pan American Health",
      "extractCut": true
    },
    {
      "id": "sec-002-preface",
      "number": null,
      "title": "Preface",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 11,
      "labelStart": "vii",
      "labelEnd": "1",
      "words": 236,
      "summary": {
        "text": "The preface explains that the Immunological Basis for Immunization series began in 1993 with eight modules on the vaccines of the Expanded Programme on Immunization and has been widely used. It notes that the series is being updated and extended with new modules, including this one on mumps.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "immunological basis",
          "heading": false
        },
        {
          "term": "immunization",
          "heading": false
        },
        {
          "term": "modules",
          "heading": false
        },
        {
          "term": "epi",
          "heading": false
        },
        {
          "term": "series",
          "heading": false
        },
        {
          "term": "papers",
          "heading": false
        },
        {
          "term": "vaccines",
          "heading": false
        }
      ],
      "extract": "This module is part of the series The Immunological Basis for Immunization, which was initially developed in 1993 as a set of eight modules focusing on the vaccines included in the Expanded Programme on Immunization (EPI)1. In addition to a general immunology module, each of the seven other modules covered one of the vaccines recommended as part of the EPI programme, i.e. diphtheria, measles, pertussis, polio,",
      "extractCut": true
    },
    {
      "id": "sec-003-1-mumps-disease-and-virus",
      "number": "1",
      "title": "Mumps disease and virus",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-004-11-mumps-disease",
      "number": "1.1",
      "title": "Mumps disease",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 12,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 622,
      "summary": {
        "text": "Describes mumps as an acute viral illness marked by swelling of the parotid or other salivary glands, spread by contact with respiratory droplets or saliva and less infectious than measles or varicella. It explains how the virus replicates and spreads in the body and the timing of infectiousness. It lists complications such as orchitis, meningitis, encephalitis and deafness, with their frequencies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps disease",
          "heading": true
        },
        {
          "term": "mumps virus",
          "heading": false
        },
        {
          "term": "mumps cases",
          "heading": false
        },
        {
          "term": "salivary glands",
          "heading": false
        },
        {
          "term": "witte karchmer",
          "heading": false
        },
        {
          "term": "laurence mcgavin",
          "heading": false
        },
        {
          "term": "parotitis",
          "heading": false
        },
        {
          "term": "incubation period",
          "heading": false
        }
      ],
      "extract": "Mumps disease Mumps is an acute viral illness characterized by unilateral or bilateral tenderness or swelling of the parotid or other salivary glands. Mumps is transmitted through person-to-person contact or by direct contact with respiratory droplets or saliva from an infected person. By comparison to measles and varicella, which can be transmitted by aerosol spread, mumps is less infectious (Hope-Simpson, 1952).",
      "extractCut": true
    },
    {
      "id": "sec-005-12-mumps-virus",
      "number": "1.2",
      "title": "Mumps virus",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 245,
      "summary": {
        "text": "Describes the mumps virus as an enveloped, negative-sense RNA virus in the Paramyxoviridae family, with its size, genome and the proteins encoded by its genes. It notes the roles of the structural and nonstructural proteins and the genotyping scheme.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps virus",
          "heading": true
        },
        {
          "term": "protein",
          "heading": false
        },
        {
          "term": "genotypes",
          "heading": false
        },
        {
          "term": "jin",
          "heading": false
        },
        {
          "term": "membrane",
          "heading": false
        },
        {
          "term": "genome",
          "heading": false
        }
      ],
      "extract": "Mumps virus Mumps virus is a single-stranded, negative sense, enveloped ribonucleic acid (RNA) virus in the Paramyxoviridae family, Paramyxovirinae sub-family, genus Rubulavirus. Mumps virions are pleomorphic but generally spherical structures, and range in size from 85 nm to 300 nm in diameter (Cantell, 1961). The viral genome is 15 384 nucleotides in length and encodes nine proteins from seven genes. The mumps",
      "extractCut": true
    },
    {
      "id": "sec-006-13-mumps-vaccines",
      "number": "1.3",
      "title": "Mumps vaccines",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 17,
      "labelStart": "2",
      "labelEnd": "7",
      "words": 1574,
      "summary": {
        "text": "Reviews mumps vaccines from the first inactivated vaccine of 1946, discontinued because immunity was short-lived, to the many live attenuated strains used since. It describes strains such as Jeryl Lynn, Urabe, Leningrad-3 and others, including how they were developed. A table compares reported rates of aseptic meningitis after vaccination with different strains in various countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps vaccines",
          "heading": true
        },
        {
          "term": "lynn strain",
          "heading": false
        },
        {
          "term": "rubini strain",
          "heading": false
        },
        {
          "term": "jeryl lynn",
          "heading": false
        },
        {
          "term": "mumps vaccination",
          "heading": false
        },
        {
          "term": "chick embryo",
          "heading": false
        },
        {
          "term": "vaccine containing",
          "heading": false
        },
        {
          "term": "aseptic meningitis",
          "heading": false
        }
      ],
      "extract": "Mumps vaccines The first mumps vaccine was developed in 1946 (Habel, 1946). It was based on formalin- inactivated virus, but was discontinued because immunity was short-lived (Habel, 1951). Since then numerous mumps vaccine strains have been developed and used in vaccines throughout the world. These vaccines have varied efficacy and safety profiles. 3 1.3.1 Jeryl Lynn The first live attenuated mumps vaccine using",
      "extractCut": true
    },
    {
      "id": "sec-007-2-immunological-response-to-natural-infection",
      "number": "2",
      "title": "Immunological response to natural infection",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 59,
      "summary": {
        "text": "Notes that immunity after natural mumps infection probably involves both antibodies and cellular immunity, that no definitive correlates of protection exist, and that research is limited compared with measles and rubella.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "immune response",
          "heading": false
        },
        {
          "term": "mumps",
          "heading": false
        },
        {
          "term": "infection",
          "heading": true
        }
      ],
      "extract": "The immune response to mumps virus infection is likely to be the result of a complex interplay between both the humoral and cellular arms of the immune response, and no definitive correlates of protection have yet been identified. Studies on the immune response to mumps infection are quite limited in comparison to those described for measles and rubella infections.",
      "extractCut": false
    },
    {
      "id": "sec-008-21-antibody-response-to-mumps-infection-in-unvac",
      "number": "2.1",
      "title": "Antibody response to mumps infection in unvaccinated individuals",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 166,
      "summary": {
        "text": "Describes the antibody response to mumps in unvaccinated people, with IgM appearing within days of symptoms and peaking around one week. IgG rises to a peak in about three weeks and persists, while salivary IgA can be detected for several weeks.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "symptom onset",
          "heading": false
        },
        {
          "term": "antibody",
          "heading": true
        },
        {
          "term": "mumps",
          "heading": true
        },
        {
          "term": "igg",
          "heading": false
        },
        {
          "term": "ukkonen",
          "heading": false
        }
      ],
      "extract": "Antibody response to mumps infection in unvaccinated individuals In naive individuals immunoglobulin M (IgM) antibodies are measurable within a few days of symptom onset. IgM peaks about one week after the onset of parotitis or symptoms, and is detectable for weeks to months after parotitis onset (Ukkonen et al., 1981; Benito et al., 1987). Low avidity IgG may also be present at the time of symptom onset, although",
      "extractCut": true
    },
    {
      "id": "sec-009-22-cell-mediated-immunity-following-natural-mump",
      "number": "2.2",
      "title": "Cell-mediated immunity following natural mumps disease",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 164,
      "summary": {
        "text": "Describes cell-mediated immunity after natural mumps, noting that lymphocytes are thought to aid recovery but that little is known about mumps-specific cellular immunity. It cites studies linking cytotoxic and proliferative lymphocyte responses with infection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "natural mumps",
          "heading": true
        },
        {
          "term": "mumps disease",
          "heading": true
        },
        {
          "term": "cell-mediated immunity",
          "heading": true
        },
        {
          "term": "correlate",
          "heading": false
        },
        {
          "term": "mumps-specific",
          "heading": false
        }
      ],
      "extract": "Cell-mediated immunity following natural mumps disease Lymphocytes are known to play an important role in host response to viral infections, and are believed to have a significant function in the immune response to mumps and recovery from mumps infection. While the presence of a plaque reduction neutralization titre to mumps appears to be associated with the development of mumps immunity, less is known about the",
      "extractCut": true
    },
    {
      "id": "sec-010-23-maternal-antibody",
      "number": "2.3",
      "title": "Maternal antibody",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 177,
      "summary": {
        "text": "Explains that maternal antibodies to mumps cross the placenta and likely protect infants, citing lower mumps rates in infants under one year. It reports studies on how long maternal antibodies remain detectable during the first year.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "maternal antibody",
          "heading": true
        },
        {
          "term": "clinical mumps",
          "heading": false
        },
        {
          "term": "detectable neutralizing",
          "heading": false
        },
        {
          "term": "neutralizing antibodies",
          "heading": false
        },
        {
          "term": "age months",
          "heading": false
        }
      ],
      "extract": "Maternal antibody Maternal antibody (IgG) to mumps following natural infection is transferred across the placenta and is believed to provide protection to infants against clinical mumps. Clinical mumps occurs less frequently in infants aged less than one year (12% to 17%) compared to children aged one to four years (68%) (Philip et al., 1959; Meyer, 1962; Reed et al., 1967). Also, during an outbreak, two out of",
      "extractCut": true
    },
    {
      "id": "sec-011-24-duration-of-immunity-to-natural-mumps-infecti",
      "number": "2.4",
      "title": "Duration of immunity to natural mumps infection",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 80,
      "summary": {
        "text": "Explains that natural mumps infection is generally thought to give long-lasting immunity, though confirmed reinfections have been reported and may be more common than believed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "natural mumps",
          "heading": true
        },
        {
          "term": "immunity",
          "heading": true
        },
        {
          "term": "infection",
          "heading": true
        }
      ],
      "extract": "Duration of immunity to natural mumps infection Natural mumps virus infection is generally believed to provide long-lasting immunity. Twenty or more years after their mumps illness, most (82%) individuals still had detectable haemagglutination-inhibiting antibodies (Levitt et al., 1970). However, cases of clinically apparent mumps reinfection that have been confirmed with epidemiological links or laboratory tests",
      "extractCut": true
    },
    {
      "id": "sec-012-3-immunological-response-to-vaccination",
      "number": "3",
      "title": "Immunological response to vaccination",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-013-31-antibody-response-following-vaccination",
      "number": "3.1",
      "title": "Antibody response following vaccination",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 21,
      "labelStart": "9",
      "labelEnd": "11",
      "words": 881,
      "summary": {
        "text": "Reports that over 90% of children develop mumps antibodies after vaccination, with similar seroconversion across major vaccine strains, and discusses responses to one and two doses. A table summarizes seroconversion studies. It notes that revaccination raised antibody titres in more than half of recipients and reduced the share with low titres.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "jeryl lynn",
          "heading": false
        },
        {
          "term": "mumps vaccine",
          "heading": false
        },
        {
          "term": "following vaccination",
          "heading": true
        },
        {
          "term": "antibody",
          "heading": true
        },
        {
          "term": "antibody titres",
          "heading": false
        },
        {
          "term": "neutralizing antibody",
          "heading": false
        },
        {
          "term": "seroconversion rates",
          "heading": false
        },
        {
          "term": "vaccines containing",
          "heading": false
        }
      ],
      "extract": "Antibody response following vaccination In general, over 90% of infants and children develop detectable antibodies against mumps following vaccination with mumps vaccines (Table 2). Seroconversion rates are comparable for vaccine combinations with Jeryl Lynn, RIT 4385 and Urabe Am 9 strains (Isomura et al., 1973; Vesikari et al., 1983b; Usonis et al., 1998; Usonis et al., 1999; Usonis et al., 2001; Lee et al., 2002)",
      "extractCut": true
    },
    {
      "id": "sec-014-33-cell-mediated-immunity-following-mumps-vaccin",
      "number": "3.3",
      "title": "Cell-mediated immunity following mumps vaccination",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 121,
      "summary": {
        "text": "Reports that most vaccinated children with mumps antibodies also show lymphocyte responses, that cellular responses are similar across ages regardless of maternal antibody, and that HLA associations suggest genetic influence on the immune response.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps",
          "heading": true
        },
        {
          "term": "mumps antigen",
          "heading": false
        },
        {
          "term": "immune response",
          "heading": false
        },
        {
          "term": "bruserud",
          "heading": false
        }
      ],
      "extract": "Cell-mediated immunity following mumps vaccination Following vaccination with live attenuated mumps vaccine, most, but not all children with anti-mumps antibody in their sera, demonstrated a lymphocyte proliferative response to mumps antigen (Ilonen, 1979; Ilonen et al., 1984). Unlike the humoral immune response to mumps, cellular responses were equivalent in all age groups and were independent of the presence of",
      "extractCut": true
    },
    {
      "id": "sec-015-34-duration-of-immunity-to-mumps-vaccination",
      "number": "3.4",
      "title": "Duration of immunity to mumps vaccination",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 488,
      "summary": {
        "text": "Notes that data on long-term immunity after mumps vaccination are limited, though antibodies persist in most people about ten years after one MMR dose, with variation by laboratory method. It discusses waning antibody levels after two doses. It ends by listing open questions on cellular immunity and boosting from exposure to wild virus.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps",
          "heading": true
        },
        {
          "term": "mumps antibodies",
          "heading": false
        },
        {
          "term": "mumps vaccine",
          "heading": false
        },
        {
          "term": "against mumps",
          "heading": false
        },
        {
          "term": "neutralizing antibody",
          "heading": false
        },
        {
          "term": "immunity",
          "heading": true
        },
        {
          "term": "lebaron",
          "heading": false
        },
        {
          "term": "antibody levels",
          "heading": false
        }
      ],
      "extract": "Duration of immunity to mumps vaccination Data regarding long-term immunity against mumps after vaccination are limited. Studies indicate that one dose of MMR vaccine can provide persistent antibodies to mumps. Between 70% and 99% of individuals had detectable anti-mumps antibodies using enzyme-linked immunosorbent assay (ELISA) or neutralization tests approximately ten years after initial vaccination (Broliden et",
      "extractCut": true
    },
    {
      "id": "sec-016-35-correlates-of-immunity",
      "number": "3.5",
      "title": "Correlates of immunity",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 24,
      "labelStart": "12",
      "labelEnd": "14",
      "words": 397,
      "summary": {
        "text": "Discusses correlates of immunity to mumps, explaining that neutralizing antibodies seem a reasonable marker though no serological test reliably predicts protection. It calls for more research, including on cell-mediated immunity markers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps igg",
          "heading": false
        },
        {
          "term": "neutralizing antibodies",
          "heading": false
        },
        {
          "term": "neutralizing antibody",
          "heading": false
        },
        {
          "term": "mumps infection",
          "heading": false
        },
        {
          "term": "immunity",
          "heading": true
        },
        {
          "term": "anti-mumps igg",
          "heading": false
        },
        {
          "term": "correlates",
          "heading": true
        },
        {
          "term": "protection against",
          "heading": false
        }
      ],
      "extract": "Correlates of immunity Humoral immunity is important in protection against mumps, and antibody measurements are often used as a surrogate measure of immunity to viral infections. However, there is poor correlation between assays that measure neutralization and less labour-intensive methods that measure the presence of mumps antibody (Pipkin et al., 1999). While no serological test available for mumps consistently",
      "extractCut": true
    },
    {
      "id": "sec-017-4-laboratory-diagnosis-of-mumps",
      "number": "4",
      "title": "Laboratory diagnosis of mumps",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 54,
      "summary": {
        "text": "Notes that mumps is often diagnosed clinically from parotitis but that laboratory confirmation may be needed because other causes exist and mumps is becoming rare.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps",
          "heading": true
        },
        {
          "term": "parotitis",
          "heading": false
        },
        {
          "term": "laboratory",
          "heading": true
        }
      ],
      "extract": "14 A clinical diagnosis of mumps is frequently made when parotitis is evident at the time of patient examination. However, since parotitis may be caused by other viral or non- viral diseases or conditions, laboratory confirmation using virological or serological techniques may be needed, especially as mumps disease becomes rare due to increased vaccination.",
      "extractCut": false
    },
    {
      "id": "sec-018-41-virological-methods",
      "number": "4.1",
      "title": "Virological methods",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 210,
      "summary": {
        "text": "Describes virological methods for diagnosing mumps, including virus stability in storage, specimen types and timing of collection. It notes that RNA detection by RT-PCR is generally more sensitive than culture.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps rna",
          "heading": false
        },
        {
          "term": "mumps virus",
          "heading": false
        },
        {
          "term": "rna detection",
          "heading": false
        },
        {
          "term": "virological",
          "heading": true
        },
        {
          "term": "methods",
          "heading": true
        },
        {
          "term": "onset",
          "heading": false
        }
      ],
      "extract": "Virological methods Mumps virus is stable for several days at 4°C. Stability increases with decreasing temperature and the virus can be stored indefinitely at -70°C. Specimen quality appears to greatly impact the ability to culture mumps virus and detect mumps RNA using reverse transcriptase-polymerase chain reaction (RT-PCR) (Utz et al., 1958). Mumps virus and RNA can be detected from blood, saliva, cerebrospinal",
      "extractCut": true
    },
    {
      "id": "sec-019-42-serological-methods",
      "number": "4.2",
      "title": "Serological methods",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 511,
      "summary": {
        "text": "Describes serological diagnosis of mumps, explaining that IgM detection works well in unvaccinated patients if specimens are well timed but may fail in vaccinated people with a secondary immune response. A table sets out expected laboratory results by vaccination status and timing of collection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "igm elisa",
          "heading": false
        },
        {
          "term": "igm response",
          "heading": false
        },
        {
          "term": "convalescent serum",
          "heading": false
        },
        {
          "term": "mumps",
          "heading": false
        },
        {
          "term": "vaccine failure",
          "heading": false
        },
        {
          "term": "vaccinated individuals",
          "heading": false
        },
        {
          "term": "serum collected",
          "heading": false
        },
        {
          "term": "secondary vaccine",
          "heading": false
        }
      ],
      "extract": "Serological methods Detection of mumps-specific IgM antibody in serum or saliva is a good diagnostic measure in unvaccinated patients. Timing of specimen collection is important to consider in interpreting laboratory results. Negative IgM ELISA results may occur when serum is collected prior to day four of clinical presentation (Cunningham et al., 2006; Krause et al., 2007). By contrast, patients who mount a",
      "extractCut": true
    },
    {
      "id": "sec-020-43-diagnostic-challenges",
      "number": "4.3",
      "title": "Diagnostic challenges",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 117,
      "summary": {
        "text": "Explains that laboratory diagnosis of mumps is difficult in highly vaccinated populations, as shown in the 2006 US outbreak, and that RT-PCR and culture are the best current tests for vaccinated people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps",
          "heading": false
        },
        {
          "term": "diagnostic",
          "heading": true
        },
        {
          "term": "dayan",
          "heading": false
        },
        {
          "term": "bitsko",
          "heading": false
        }
      ],
      "extract": "Diagnostic challenges Laboratory diagnosis of mumps in highly-vaccinated populations is challenging, and new laboratory tools and diagnostic approaches are needed to accurately identify cases and better understand the epidemiology of mumps in highly-vaccinated populations. During the 2006 mumps outbreak in the USA, the majority of patients who had received two doses of MMR and presented with symptoms that were",
      "extractCut": true
    },
    {
      "id": "sec-021-5-vaccine-performance",
      "number": "5",
      "title": "Vaccine performance",
      "level": 1,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 1,
      "summary": {
        "text": "A section heading for vaccine performance, containing only a page number.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "16",
      "extractCut": false
    },
    {
      "id": "sec-022-51-vaccine-efficacy",
      "number": "5.1",
      "title": "Vaccine efficacy",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 109,
      "summary": {
        "text": "Reports prelicensure studies showing a single dose of Jeryl Lynn mumps vaccine was about 95% effective over short follow-up, and high efficacy for Leningrad-3 strain vaccines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "leningrad strain",
          "heading": false
        },
        {
          "term": "efficacy",
          "heading": true
        },
        {
          "term": "mumps",
          "heading": false
        }
      ],
      "extract": "Vaccine efficacy Prelicensure studies conducted in over 7000 children enrolled in nursery or elementary schools found a single dose of mumps vaccines containing the Jeryl Lynn strain to be approximately 95% effective in preventing mumps disease (Hilleman et al., 1967; Weibel et al., 1967; Sugg et al., 1968). However, duration of follow-up was short (up to 20 months). In a smaller study, with 193 children exposed to",
      "extractCut": true
    },
    {
      "id": "sec-023-52-vaccine-effectiveness",
      "number": "5.2",
      "title": "Vaccine effectiveness",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 30,
      "labelStart": "16",
      "labelEnd": "20",
      "words": 1377,
      "summary": {
        "text": "Reviews postlicensure vaccine effectiveness from outbreak studies, with a median of 79% for one dose of Jeryl Lynn vaccine and lower figures for the Urabe strain. It reports that the Rubini strain showed little or no effectiveness and is no longer available. Two-dose Jeryl Lynn effectiveness had a median of 88%, usually but not significantly higher than one dose. It calls for research linking protection to neutralizing antibody levels and on the role of heterologous mumps strains.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaccine effectiveness",
          "heading": true
        },
        {
          "term": "mumps vaccine",
          "heading": false
        },
        {
          "term": "lynn mumps",
          "heading": false
        },
        {
          "term": "jeryl lynn",
          "heading": false
        },
        {
          "term": "lynn strain",
          "heading": false
        },
        {
          "term": "rit strain",
          "heading": false
        },
        {
          "term": "rubini strain",
          "heading": false
        },
        {
          "term": "received mumps",
          "heading": false
        }
      ],
      "extract": "Vaccine effectiveness 5.2.1 Vaccine effectiveness of one dose In postlicensure studies, vaccine effectiveness estimates for prevention of mumps disease have been lower (Table 5). In 18 studies from outbreaks (primarily school children) in North America and Europe, the median estimate for vaccine effectiveness of one dose of the Jeryl Lynn mumps vaccine was 79% (range: 62% to 91%) (Lewis et al., 1979; Kim-Farley et",
      "extractCut": true
    },
    {
      "id": "sec-024-references",
      "number": null,
      "title": "References",
      "level": 1,
      "pageStart": 30,
      "pageEnd": 44,
      "labelStart": "20",
      "labelEnd": "34",
      "words": 5764,
      "summary": {
        "text": "The reference list for the mumps module, citing mainly published studies on mumps epidemiology, vaccine safety and effectiveness, immunology and laboratory diagnosis. It ends with WHO's Department of Immunization, Vaccines and Biologicals contact details and the ISBN.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mumps rubella",
          "heading": false
        },
        {
          "term": "attenuated mumps",
          "heading": false
        },
        {
          "term": "measles mumps",
          "heading": false
        },
        {
          "term": "mumps vaccine",
          "heading": false
        },
        {
          "term": "mumps strain",
          "heading": false
        },
        {
          "term": "live mumps",
          "heading": false
        },
        {
          "term": "urabe mumps",
          "heading": false
        },
        {
          "term": "mumps virus",
          "heading": false
        }
      ],
      "extract": "20 Afzal MA et al. (1993). The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. The Journal of General Virology, 74 (Pt. 5):917–920. Al-Mazrou Y et al. (2002). Safety evaluation of MMR vaccine during a primary school campaign in Saudi Arabia. Journal of Tropical Pediatrics, 48(6):354–358. Arday DR et al. (1989). Mumps in the US Army 1980–86: should recruits be immunized? American",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 1,
        "items": [
          "3.2 Immune responses to revaccination"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 7,
      "items": [
        "p4: pdf-labels iv, printed ii",
        "p5: pdf-labels v, printed iii",
        "p6: pdf-labels vi, printed iv",
        "p7: pdf-labels vii, printed v, contents v",
        "p8: pdf-labels viii, printed vi",
        "p9: pdf-labels ix, printed vii, contents vii",
        "p10: pdf-labels x, printed viii"
      ]
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "mumps vaccine",
      "heading": true
    },
    {
      "term": "mumps antibody",
      "heading": true
    },
    {
      "term": "mumps strain",
      "heading": false
    },
    {
      "term": "mumps antibodies",
      "heading": true
    },
    {
      "term": "lynn mumps",
      "heading": false
    },
    {
      "term": "mumps virus",
      "heading": true
    },
    {
      "term": "mumps vaccination",
      "heading": true
    },
    {
      "term": "urabe mumps",
      "heading": false
    },
    {
      "term": "mumps infection",
      "heading": true
    },
    {
      "term": "measles mumps",
      "heading": false
    },
    {
      "term": "mumps igg",
      "heading": false
    },
    {
      "term": "mumps igm",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "iii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "2",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 13,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 18,
      "label": "8",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "12",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "14",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "16",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 31,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "26",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "28",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "34",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "Incidence of aseptic meningitis following mumps vaccination",
      "page": 15,
      "pageLabel": "5",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Seroconversion following mumps vaccination",
      "page": 20,
      "pageLabel": "10",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "Long-term persistence of mumps antibodies",
      "page": 21,
      "pageLabel": "11",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "Immune response to mumps wild-type infection",
      "page": 25,
      "pageLabel": "15",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5",
      "title": "Mumps vaccine effectiveness",
      "page": 27,
      "pageLabel": "17",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1: Incidence of aseptic meningitis following mumps vaccination",
      "pages": [
        15,
        16
      ],
      "columns": [
        {
          "titles": "Reference"
        },
        {
          "titles": "Country"
        },
        {
          "titles": "Number of doses"
        },
        {
          "titles": "Population vaccinated"
        },
        {
          "titles": "Ascertainment of cases"
        },
        {
          "titles": "Incidence per 100 000 doses"
        }
      ],
      "rows": [
        [
          "Jeryl Lynn/RIT 4385",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "(Fescharek et al., 1990)",
          "Germany",
          "~5 500 000",
          "",
          "Drug side-effect surveillance",
          "0.1"
        ],
        [
          "(Schlipkoter et al., 2002)",
          "Germany",
          "1 575 936",
          "≤15 years",
          "National hospital surveillance system",
          "<0.2"
        ],
        [
          "(Miller et al., 2007)",
          "United Kingdom",
          ">99 000",
          "12–23 months",
          "Hospital discharge diagnoses",
          "<1"
        ],
        [
          "(Black et al., 1997)",
          "United States",
          "~300 000",
          "12–23 months",
          "Hospital discharge diagnoses",
          "<1"
        ],
        [
          "Urabe Am 9",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "(Al-Mazrou et al., 2002)",
          "Saudi Arabia",
          "2 412 078",
          "6–13 years*",
          "National, hospital, and school surveillance",
          "0.3"
        ],
        [
          "(Jonville-Bera et al., 1996)",
          "France",
          "",
          "11 months – 10 years",
          "Reports to regional pharmacovigilance centres or manufacturer",
          "0.82 (95% CI: 0.77– 0.92)"
        ],
        [
          "(Furesz & Contreras, 1990)",
          "Canada",
          "250 000-300 000",
          "",
          "Laboratory reports",
          "1.6"
        ],
        [
          "(Rebiere & Galy-Eyraud, 1995)",
          "France",
          "3 290 470",
          "Children (mostly <24 months)",
          "Vaccine manufacturer’s surveillance system and laboratory surveillance",
          "3.5 (95% CI: 1.5–5.6)"
        ],
        [
          "(Farrington et al., 1995)",
          "England",
          "77 200",
          "12–24 months",
          "Hospital discharge diagnoses",
          "6.7"
        ],
        [
          "(Dourado et al., 2000)",
          "Brazil",
          "452 344",
          "1–11 years",
          "State surveillance and prospective hospital admission following mass-vaccination campaign",
          "7.1"
        ],
        [
          "(Miller et al., 2007)",
          "United Kingdom",
          "49 585",
          "12–23 months",
          "Hospital discharge diagnoses",
          "8.0 (95% CI: 2.2–21)"
        ],
        [
          "(Sugiura & Yamada, 1991)",
          "Japan",
          "630 157",
          "1–6 years",
          "Passive surveillance to Ministry of Health",
          "12–15"
        ],
        [
          "(Miller et al., 1993)",
          "United Kingdom",
          "78 300",
          "12–24 months",
          "Public Health Laboratories and hospital discharge diagnosis",
          "17"
        ],
        [
          "(Colville & Pugh, 1992)",
          "United Kingdom",
          "22 817",
          "12–24 months",
          "Laboratory records",
          "26 (95% CI: 5.3–47)"
        ],
        [
          "(Fujinaga et al., 1991)",
          "Japan",
          "11 750",
          "1–6 years",
          "Hospital surveillance",
          "110"
        ],
        [
          "(Ueda et al., 1995)",
          "Japan",
          "6542",
          "",
          "Prospective surveillance following vaccination",
          "110"
        ],
        [
          "Leningrad 3",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "(Cizman et al., 1989)",
          "Yugoslavia",
          "115 253",
          "≤15 years",
          "Hospital records",
          "100"
        ],
        [
          "L-Zagreb",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "(Pan American Health Organization, 1999)",
          "Bahamas",
          ">100 000",
          "4–40 years",
          "Surveillance activities not mentioned (note: small proportion of doses were Jeryl Lynn mumps strain)",
          "0.96"
        ],
        [
          "(Phadke et al., 2004)",
          "India",
          "190 723",
          "Children",
          "Post-marketing surveillance surveys to paediatricians (note: response rate 68%)",
          "1.0"
        ],
        [
          "(da Cunha et al., 2002)",
          "Brazil",
          "845 889",
          "Children†",
          "Routine surveillance system and hospital records",
          "5.2–16"
        ],
        [
          "(Arruda & Kondageski, 2001)",
          "Brazil",
          "590 609",
          "2–39 years",
          "National surveillance",
          "17"
        ],
        [
          "(da Silveira et al., 2002)",
          "Brazil",
          "110 629",
          "1–11 years",
          "Passive surveillance",
          "29"
        ],
        [
          "(Dos Santos et al., 2002)",
          "Brazil",
          "2 226",
          "6–12 years",
          "Active follow-up",
          "45"
        ],
        [
          "(Tesovic & Lesnikar, 2006)",
          "Croatia",
          "96 994",
          "12–46 months",
          "Prospective hospital study",
          "49 (95% CI: 36–66)"
        ],
        [
          "(Tesovic et al., 1993)",
          "Croatia",
          "",
          "10 months–6 years",
          "Hospital records",
          "90 (95% CI: 64–116)"
        ],
        [
          "Torii",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "(Ueda et al., 1995)",
          "Japan",
          "961",
          "",
          "Prospective surveillance following vaccination",
          "107"
        ],
        [
          "(Kimura et al., 1996)",
          "Japan",
          "8600",
          "1–6 years",
          "Active surveillance",
          "140"
        ],
        [
          "Hoshino",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "(Kimura et al., 1996)",
          "Japan",
          "21 717",
          "1–6 years",
          "Active surveillance",
          "126"
        ],
        [
          "(Ueda et al., 1995)",
          "Japan",
          "3603",
          "",
          "Prospective surveillance following vaccination",
          "187"
        ]
      ],
      "notes": "* Probable second dose.\n† Campaign dose, irrespective of prior vaccination history.",
      "narratives": {
        "en": "Studies of aseptic meningitis after mumps vaccination, grouped by vaccine strain (Jeryl Lynn/RIT 4385, Urabe Am 9, Leningrad 3, L-Zagreb, Torii, Hoshino). For each study the table gives the country, number of doses, population vaccinated, how cases were ascertained and the incidence per 100 000 doses.",
        "ar": "دراسات عن التهاب السحايا العقيم بعد التطعيم ضد النكاف، مجمّعة حسب سلالة اللقاح (Jeryl Lynn/RIT 4385 وUrabe Am 9 وLeningrad 3 وL-Zagreb وTorii وHoshino). ويعرض الجدول لكل دراسة البلد وعدد الجرعات والفئة السكانية المطعّمة وطريقة رصد الحالات ومعدل الوقوع لكل 100 000 جرعة.",
        "zh": "按疫苗毒株（Jeryl Lynn/RIT 4385、Urabe Am 9、Leningrad 3、L-Zagreb、Torii、Hoshino）分组列出腮腺炎疫苗接种后无菌性脑膜炎的研究。表中给出每项研究的国家、剂次数、接种人群、病例确定方式以及每10万剂的发生率。",
        "es": "Estudios sobre la meningitis aséptica tras la vacunación contra la parotiditis, agrupados por cepa vacunal (Jeryl Lynn/RIT 4385, Urabe Am 9, Leningrad 3, L-Zagreb, Torii, Hoshino). Para cada estudio se indican el país, el número de dosis, la población vacunada, el método de detección de casos y la incidencia por 100 000 dosis.",
        "fr": "Études sur la méningite aseptique après vaccination antiourlienne, regroupées par souche vaccinale (Jeryl Lynn/RIT 4385, Urabe Am 9, Leningrad 3, L-Zagreb, Torii, Hoshino). Pour chaque étude, le tableau indique le pays, le nombre de doses, la population vaccinée, le mode de détection des cas et l’incidence pour 100 000 doses.",
        "ru": "Исследования асептического менингита после вакцинации против эпидемического паротита, сгруппированные по штамму вакцины (Jeryl Lynn/RIT 4385, Urabe Am 9, Leningrad 3, L-Zagreb, Torii, Hoshino). Для каждого исследования указаны страна, число доз, вакцинированная популяция, способ выявления случаев и заболеваемость на 100 000 доз."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2: Seroconversion following mumps vaccination",
      "pages": [
        20
      ],
      "columns": [
        {
          "titles": "Strain"
        },
        {
          "titles": "Number of studies"
        },
        {
          "titles": "Median",
          "group": "Seroconversion (%)"
        },
        {
          "titles": "Range",
          "group": "Seroconversion (%)"
        },
        {
          "titles": "References"
        }
      ],
      "rows": [
        [
          "Jeryl Lynn, monovalent",
          "6",
          "95.9",
          "74.2, 99.6",
          "(Weibel et al., 1967; Hilleman et al., 1968; Sugg et al., 1968; Brunell et al., 1969; Vesikari et al., 1983b; Fedova et al., 1987)"
        ],
        [
          "Jeryl Lynn, bivalent",
          "3",
          "90.0",
          "83.5, 90.6",
          "(Weibel et al., 1973; Vesikari et al., 1983a; Popow-Kraupp et al., 1986)"
        ],
        [
          "Jeryl Lynn, trivalent",
          "11",
          "94",
          "89, 97",
          "(Borgono et al., 1973; Ehrenkranz et al., 1975; Schwarz et al., 1975; Lerman et al., 1981; Popow-Kraupp et al., 1986; Schwarzer et al., 1998; Usonis et al., 1998; Usonis et al., 1999; Klinge et al., 2000; Redd et al., 2004; Feiterna-Sperling et al., 2005)"
        ],
        [
          "Jeryl Lynn, tetravalent",
          "4",
          "99.5",
          "98, 100",
          "(Watson et al., 1996; Shinefield et al., 2005; Kuter et al., 2006; Bernstein et al., 2007)"
        ],
        [
          "RIT 4385, trivalent",
          "8",
          "96.4",
          "88, 98.6",
          "(Usonis et al., 1998; Gatchalian et al., 1999; Usonis et al., 1999; Crovari et al., 2000; Lee et al., 2002; Nolan et al., 2002; Stuck et al., 2002; Lim et al., 2007)"
        ],
        [
          "Urabe Am 9, monovalent",
          "3",
          "94.8",
          "82.6, 97",
          "(Isomura et al., 1973; Ehrengut et al., 1983; Vesikari et al., 1983b)"
        ],
        [
          "Urabe Am 9, bivalent",
          "2",
          "84.2",
          "78.7, 96.9",
          "(Vesikari et al., 1983a; Popow-Kraupp et al., 1986)"
        ],
        [
          "Urabe Am 9, trivalent",
          "5",
          "99",
          "96.9, 100",
          "(Berger et al., 1988; Robertson et al., 1988; Dunlop et al., 1989; Schoub et al., 1990; Forleo-Neto et al., 1997)"
        ],
        [
          "Rubini",
          "5",
          "93.3",
          "23.3, 95",
          "(Gluck et al., 1986; Just et al., 1986; Berger et al., 1988; Schwarzer et al., 1998; Khalil et al., 1999; Crovari et al., 2000)"
        ],
        [
          "Leningrad-3",
          "4",
          "93.5",
          "89, 98",
          "(Smorodintsev et al., 1970)"
        ],
        [
          "Leningrad-Zagreb",
          "2",
          "89.4",
          "88.1, 90.7",
          "(Beck et al., 1989)"
        ],
        [
          "BBM-18",
          "1",
          "84.8",
          "",
          "(Feiterna-Sperling et al., 2005)"
        ],
        [
          "Sofia 6",
          "2",
          "93.4",
          "92.6, 94.1",
          "(Odisseev & Gacheva, 1994)"
        ],
        [
          "Hoshino",
          "2",
          "98.4",
          "96.8, 100",
          "(Makino et al., 1990)"
        ],
        [
          "S-12",
          "1",
          "93",
          "",
          "(Sassani et al., 1991)"
        ]
      ],
      "narratives": {
        "en": "Seroconversion after mumps vaccination by vaccine strain and formulation (monovalent, bivalent, trivalent, tetravalent). For each strain the table gives the number of studies, the median and range of seroconversion (%) and the references.",
        "ar": "التحول المصلي بعد التطعيم ضد النكاف حسب سلالة اللقاح وتركيبته (أحادي التكافؤ أو ثنائي أو ثلاثي أو رباعي التكافؤ). ويعرض الجدول لكل سلالة عدد الدراسات والوسيط والمدى للتحول المصلي (%) والمراجع.",
        "zh": "按疫苗毒株和剂型（单价、二价、三价、四价）列出腮腺炎疫苗接种后的血清阳转情况。表中给出每种毒株的研究数量、血清阳转率（%）的中位数和范围以及参考文献。",
        "es": "Seroconversión tras la vacunación contra la parotiditis según la cepa y la formulación de la vacuna (monovalente, bivalente, trivalente, tetravalente). Para cada cepa se indican el número de estudios, la mediana y el intervalo de seroconversión (%) y las referencias.",
        "fr": "Séroconversion après vaccination antiourlienne selon la souche et la formulation du vaccin (monovalent, bivalent, trivalent, tétravalent). Pour chaque souche, le tableau indique le nombre d’études, la médiane et l’intervalle de séroconversion (%) ainsi que les références.",
        "ru": "Сероконверсия после вакцинации против эпидемического паротита в зависимости от штамма и состава вакцины (моно-, би-, три- и тетравалентная). Для каждого штамма приведены число исследований, медиана и диапазон сероконверсии (%) и ссылки."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3: Long-term persistence of mumps antibodies following vaccination with mumps Jeryl Lynn vaccine",
      "pages": [
        21
      ],
      "columns": [
        {
          "titles": "Reference"
        },
        {
          "titles": "Country"
        },
        {
          "titles": "Years after vaccination"
        },
        {
          "titles": "Number seropositive/ Number tested (%)"
        },
        {
          "titles": "Serological method used"
        }
      ],
      "rows": [
        [
          "1 dose",
          "",
          "",
          "",
          ""
        ],
        [
          "(LeBaron et al., 2009)",
          "United States",
          "10",
          "304/308 (99)",
          "Plaque-reduction neutralization"
        ],
        [
          "(Gothefors et al., 2001)",
          "Sweden",
          "~10",
          "230/299 (70)",
          "ELISA"
        ],
        [
          "(Broliden et al., 1998)",
          "Sweden",
          "~11",
          "167/229 (73)",
          "Neutralizing antibodies"
        ],
        [
          "2 doses",
          "",
          "",
          "",
          ""
        ],
        [
          "(LeBaron et al., 2009)",
          "United States",
          "7",
          "17/189 (91)",
          "Plaque-reduction neutralization"
        ],
        [
          "(Date et al., 2008)",
          "United States",
          "≥11",
          "134/146 (92)",
          "Commercial EIA"
        ],
        [
          "(LeBaron et al., 2009)",
          "United States",
          "12",
          "146/154 (95)*",
          "Plaque-reduction neutralization"
        ],
        [
          "(Davidkin et al., 2008)",
          "Finland",
          "15",
          "67/90 (74)",
          "Commercial EIA"
        ]
      ],
      "notes": "* All subjects were seropositive prior to receipt of second mumps vaccine.",
      "narratives": {
        "en": "Studies of long-term persistence of mumps antibodies after one or two doses of Jeryl Lynn mumps vaccine. For each study the table gives the country, years since vaccination, the number seropositive out of the number tested (%) and the serological method used.",
        "ar": "دراسات عن استمرار الأضداد المضادة للنكاف على المدى الطويل بعد جرعة واحدة أو جرعتين من لقاح النكاف Jeryl Lynn. ويعرض الجدول لكل دراسة البلد وعدد السنوات منذ التطعيم وعدد الإيجابيين مصلياً من عدد المفحوصين (%) والطريقة المصلية المستخدمة.",
        "zh": "关于接种一剂或两剂Jeryl Lynn腮腺炎疫苗后腮腺炎抗体长期持久性的研究。表中给出每项研究的国家、接种后年数、血清阳性人数/检测人数（%）以及所用血清学方法。",
        "es": "Estudios sobre la persistencia a largo plazo de los anticuerpos contra la parotiditis tras una o dos dosis de la vacuna Jeryl Lynn. Para cada estudio se indican el país, los años transcurridos desde la vacunación, el número de seropositivos sobre el número de examinados (%) y el método serológico utilizado.",
        "fr": "Études sur la persistance à long terme des anticorps antiourliens après une ou deux doses de vaccin Jeryl Lynn. Pour chaque étude, le tableau indique le pays, le nombre d’années depuis la vaccination, le nombre de sujets séropositifs sur le nombre testé (%) et la méthode sérologique utilisée.",
        "ru": "Исследования длительного сохранения антител к вирусу паротита после одной или двух доз вакцины Jeryl Lynn. Для каждого исследования указаны страна, число лет после вакцинации, число серопозитивных из числа обследованных (%) и использованный серологический метод."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4: Immune response to mumps wild-type infection based on exposure history",
      "pages": [
        25
      ],
      "columns": [
        {
          "titles": "Previous infection history"
        },
        {
          "titles": "IgM"
        },
        {
          "titles": "IgG"
        },
        {
          "titles": "Avidity"
        },
        {
          "titles": "Comments"
        },
        {
          "titles": "References"
        }
      ],
      "rows": [
        [
          "Unvaccinated No history of mumps",
          "+",
          "+ or -",
          "Low",
          "IgM may be detected for weeks to months Low levels of low avidity IgG may be present at disease onset",
          "(Meurman et al.. 1982; Sakata et al., 1985)"
        ],
        [
          "Previously vaccinated 1 dose",
          "+ or -",
          "Likely +",
          "Low: primary vaccine failure High: secondary vaccine failure",
          "Serum collected: 1–10 days: 50% IgM+ >10 days: 50%–80% IgM +",
          "(Narita et al., 1998; Jin et al., 2004; Krause et al., 2007)"
        ],
        [
          "Previously vaccinated 2 doses",
          "+ or -",
          "Likely +",
          "Low: primary vaccine failure High: secondary vaccine failure",
          "Serum Collected: 1–3 days: 12%–14% IgM+",
          "(Bitsko et al., 2008; Rota et al., 2009)"
        ],
        [
          "Wild-type mumps",
          "+ or -",
          "+",
          "High",
          "IgM infrequently detected",
          ""
        ]
      ],
      "narratives": {
        "en": "Expected antibody findings in wild-type mumps infection according to prior exposure (unvaccinated, one or two vaccine doses, previous wild-type infection). Columns give IgM, IgG and avidity results, comments on IgM detection, and references.",
        "ar": "النتائج المتوقعة للأضداد في عدوى النكاف بالنمط البري بحسب التعرض السابق (غير مطعّم، أو تلقى جرعة أو جرعتين من اللقاح، أو عدوى سابقة بالنمط البري). وتعرض الأعمدة نتائج IgM وIgG والشراهة وملاحظات عن كشف IgM والمراجع.",
        "zh": "按既往暴露情况（未接种、接种一剂或两剂疫苗、既往野生型感染）列出野生型腮腺炎感染时预期的抗体结果。各列给出IgM、IgG和亲和力结果、关于IgM检出的说明以及参考文献。",
        "es": "Resultados esperados de anticuerpos en la infección por el virus salvaje de la parotiditis según la exposición previa (no vacunado, una o dos dosis de vacuna, infección salvaje previa). Las columnas presentan los resultados de IgM, IgG y avidez, comentarios sobre la detección de IgM y las referencias.",
        "fr": "Résultats sérologiques attendus lors d’une infection ourlienne par le virus sauvage selon l’exposition antérieure (non vacciné, une ou deux doses de vaccin, infection sauvage antérieure). Les colonnes indiquent les résultats IgM, IgG et d’avidité, des commentaires sur la détection des IgM et les références.",
        "ru": "Ожидаемые результаты определения антител при инфекции диким вирусом паротита в зависимости от предшествующего воздействия (невакцинированные, одна или две дозы вакцины, ранее перенесённая инфекция диким вирусом). В столбцах приведены результаты IgM, IgG и авидности, комментарии по выявлению IgM и ссылки."
      },
      "csv": "tables/table-4.csv"
    },
    {
      "label": "Table 5",
      "caption": "Table 5: Mumps vaccine effectiveness",
      "pages": [
        27,
        28
      ],
      "columns": [
        {
          "titles": "Reference"
        },
        {
          "titles": "Country"
        },
        {
          "titles": "Population"
        },
        {
          "titles": "Number in study"
        },
        {
          "titles": "Vaccine effectiveness (%)"
        }
      ],
      "rows": [
        [
          "Jeryl Lynn — one dose",
          "",
          "",
          "",
          ""
        ],
        [
          "(Chamot et al., 1998)",
          "Switzerland",
          "Close contacts",
          "",
          "62 (95% CI: 0, 85)"
        ],
        [
          "(Harling et al., 2005)",
          "England",
          "Population",
          "353",
          "64 (95% CI: 40, 78)"
        ],
        [
          "(Toscani et al., 1996)",
          "Switzerland",
          "School",
          "",
          "65 (95% CI: 11, 86)"
        ],
        [
          "(Sartorius et al., 2005)",
          "Sweden",
          "Population",
          "Screening method",
          "65"
        ],
        [
          "(Castilla et al., 2009)",
          "Spain",
          "Population (children)",
          "1057",
          "66 (95% CI: 25, 85)"
        ],
        [
          "(Richard et al., 2003)",
          "Switzerland",
          "Population (young children)",
          "324",
          "70 (95% CI: 50, 80)"
        ],
        [
          "(Lewis et al., 1979)",
          "Canada",
          "School",
          "495",
          "75"
        ],
        [
          "(Wharton et al., 1988)",
          "United States",
          "School",
          "385",
          "78 (95% CI: 65, 86)"
        ],
        [
          "(Schlegel et al., 1999)",
          "Switzerland",
          "Population (children)",
          "44",
          "78 (95% CI: 64, 82)"
        ],
        [
          "(Schaffzin et al., 2007)",
          "United States",
          "Camp attendees and staff",
          "67",
          "80 (95% CI: 42, 93)"
        ],
        [
          "(Sullivan et al., 1985)",
          "United States",
          "School",
          "434",
          "81 (95% CI: 71, 88)"
        ],
        [
          "(Ong et al., 2005)",
          "Singapore",
          "Child care centre and school",
          "1325",
          "81 (95% CI: 58, 91)"
        ],
        [
          "(Cheek et al., 1995)",
          "United States",
          "School",
          "307",
          "82 (95% CI: 77, 86)"
        ],
        [
          "(Marin et al., 2008)",
          "United States",
          "College population",
          "235",
          "82 (95% CI: 0, 98)"
        ],
        [
          "(Hersh et al., 1991)",
          "United States",
          "School",
          "1721",
          "83 (95% CI: 57, 94)"
        ],
        [
          "(Kim-Farley et al., 1985)",
          "United States",
          "School",
          "66",
          "85 (95% CI: 39, 94)"
        ],
        [
          "(Cohen et al., 2007)*",
          "England",
          "Population",
          "Screening method",
          "88 (95% CI: 83, 91)"
        ],
        [
          "(Chaiken et al., 1987)",
          "United States",
          "School",
          "165",
          "91 (95% CI: 77, 93)"
        ],
        [
          "Jeryl Lynn — two doses",
          "",
          "",
          "",
          ""
        ],
        [
          "(Marin et al., 2008)",
          "United States",
          "College population",
          "2141",
          "79 (95% CI: 0, 97)"
        ],
        [
          "(Castilla et al., 2009)",
          "Spain",
          "Population (children)",
          "425",
          "83 (95% CI: 54, 94)"
        ],
        [
          "(Harling et al., 2005)*",
          "England",
          "Population",
          "153",
          "88 (95% CI: 62, 96)"
        ],
        [
          "(Marin et al., 2008)",
          "United States",
          "Close contacts",
          "74",
          "88 (95% CI: 63, 96)"
        ],
        [
          "(Sartorius et al., 2005)",
          "Sweden",
          "Population",
          "Screening method",
          "91"
        ],
        [
          "(Schaffzin et al., 2007)",
          "United States",
          "Camp population",
          "461",
          "92 (95% CI: 83, 96)"
        ],
        [
          "(Cohen et al., 2007)*",
          "England",
          "Population",
          "Screening method",
          "95 (95% CI: 93, 96)"
        ],
        [
          "Urabe Am 9",
          "",
          "",
          "",
          ""
        ],
        [
          "(Ong et al., 2005)",
          "Singapore",
          "Childcare centre and school",
          "804",
          "54 (95% CI: -16, 82)"
        ],
        [
          "(Goncalves et al., 1998)",
          "Portugal",
          "Population",
          "242",
          "70 (95% CI: 25, 88)"
        ],
        [
          "(Chamot et al., 1998)",
          "Switzerland",
          "Close contacts",
          "",
          "73 (95% CI: 42, 88)"
        ],
        [
          "(Toscani et al., 1996)",
          "Switzerland",
          "School",
          "",
          "76 (95% CI: 36, 91)"
        ],
        [
          "(Schlegel et al., 1999)",
          "Switzerland",
          "Population",
          "48",
          "87 (95% CI: 76, 94)"
        ],
        [
          "Rubini",
          "",
          "",
          "",
          ""
        ],
        [
          "(Pons et al., 2000)",
          "Spain",
          "School",
          "422",
          "-340"
        ],
        [
          "(Ong et al., 2005)",
          "Singapore",
          "Childcare centre and school",
          "2308",
          "-55 (95% CI: -122, -9)"
        ],
        [
          "(Schlegel et al., 1999)",
          "Switzerland",
          "Population",
          "87",
          "-4 (95% CI: -218, 15)"
        ],
        [
          "(Goncalves et al., 1998)",
          "Portugal",
          "Population",
          "369",
          "1 (95% CI: -108, 53)"
        ],
        [
          "(Chamot et al., 1998)",
          "Switzerland",
          "Close contacts",
          "",
          "6 (95% CI: -46, 40)"
        ],
        [
          "(Toscani et al., 1996)",
          "Switzerland",
          "School",
          "",
          "12 (95% CI: -102, 62)"
        ],
        [
          "(Pons et al., 2000)",
          "Spain",
          "School",
          "124",
          "40 (95% CI: -66, 78)"
        ],
        [
          "(Richard et al., 2003)",
          "Switzerland",
          "Population (young children)",
          "213",
          "30 (95% CI: -30, 60)"
        ],
        [
          "(Paccaud et al., 1995)",
          "Switzerland",
          "School",
          "156",
          "50 (95% CI: -19, 81)"
        ],
        [
          "Leningrad-Zagreb",
          "",
          "",
          "",
          ""
        ],
        [
          "(Beck et al., 1989)",
          "Yugoslavia",
          "Pre-school",
          "",
          "97-100"
        ],
        [
          "Leningrad-3",
          "",
          "",
          "",
          ""
        ],
        [
          "(Smorodintsev et al., 1965)",
          "",
          "School",
          "193",
          "94 (95% CI: 76, 98)"
        ],
        [
          "S79",
          "",
          "",
          "",
          ""
        ],
        [
          "(Fu et al., 2008)",
          "China",
          "Population (8 month–12 years)",
          "937",
          "86 (95% CI: 77, 92)"
        ],
        [
          "(Fu et al., 2009)",
          "China",
          "Population (8 month–12 years)",
          "366",
          "83 (95% CI: 68, 91)"
        ],
        [
          "Sofia 6",
          "",
          "",
          "",
          ""
        ],
        [
          "(Odisseev & Gacheva, 1994)",
          "Bulgaria",
          "Contacts",
          "",
          "98"
        ]
      ],
      "notes": "* Some of the study population may have received mumps vaccine containing RIT 4385 strain.",
      "narratives": {
        "en": "Post-licensure estimates of mumps vaccine effectiveness, grouped by vaccine strain and, for Jeryl Lynn, by one or two doses. For each study the table gives the country, study population, number in study and vaccine effectiveness (%) with 95% confidence intervals where available.",
        "ar": "تقديرات فعالية لقاح النكاف بعد الترخيص، مجمّعة حسب سلالة اللقاح، وحسب جرعة واحدة أو جرعتين بالنسبة إلى Jeryl Lynn. ويعرض الجدول لكل دراسة البلد والفئة السكانية المدروسة وعدد المشاركين وفعالية اللقاح (%) مع فترات الثقة 95% حيثما توفرت.",
        "zh": "按疫苗毒株分组（Jeryl Lynn再按一剂或两剂细分）列出上市后腮腺炎疫苗效果的估计值。表中给出每项研究的国家、研究人群、研究人数以及疫苗效果（%）及其95%置信区间（如有）。",
        "es": "Estimaciones posteriores a la autorización de la efectividad de la vacuna contra la parotiditis, agrupadas por cepa vacunal y, para Jeryl Lynn, por una o dos dosis. Para cada estudio se indican el país, la población estudiada, el número de participantes y la efectividad vacunal (%) con intervalos de confianza del 95% cuando se dispone de ellos.",
        "fr": "Estimations post-homologation de l’efficacité sur le terrain du vaccin antiourlien, regroupées par souche vaccinale et, pour Jeryl Lynn, par une ou deux doses. Pour chaque étude, le tableau indique le pays, la population étudiée, l’effectif et l’efficacité vaccinale (%) avec, le cas échéant, l’intervalle de confiance à 95 %.",
        "ru": "Пострегистрационные оценки эффективности вакцины против эпидемического паротита, сгруппированные по штамму вакцины, а для Jeryl Lynn — по одной или двум дозам. Для каждого исследования указаны страна, изучаемая популяция, число участников и эффективность вакцины (%) с 95% доверительными интервалами, если они имеются."
      },
      "csv": "tables/table-5.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 26,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 26,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "none"
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 5
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p30); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p7); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 24,
      "note": "24 of 26 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-97885"
  }
}
